Ten billion varieties of 3 pharmaceutical companies have been rated: Shuangyu, Qilu, Zhengda sunny.

1, the rapid growth of the billion-dollar star varieties recently, Beijing Shuangyu Pharmaceuticals announced that the company's products to nadoamine capsules through consistency evaluation, after Zhengda Qing and Qilu Pharmaceuticals, the third domestic evaluation of the enterprise.
Shuangyu Pharmaceuticals said in the announcement that the consistency evaluation of nadoamine capsules will be conducive to replacing the original research products, improve the market competitiveness and market share of the products, the future business performance has a positive impact.
public information shows that the indomine is a first-line drug of multiple myeloma, as a new generation of immunomodulator, with immunomodulation, anti-angiogenesis and anti-tumor characteristics, clinically widely used in multiple myeloma, lymphoma, myelomication abnormal syndrome, acute myeloid leukemia and other diseases of treatment, is currently the international and domestic treatment of multiple myeloma and myeloma myeloma and hyperplasia abnormal syndrome commonly used drugs.
as a heavy drug for the treatment of multiple myeloma, nardomine is the U.S. National Comprehensive Cancer Network Multiple myeloma guidelines 2018 version of the priority recommended drug, but also China's 2017 multiple myeloma diagnosis and treatment guidelines first-line treatment, second-line treatment, recurrence difficult to treat key drugs.
the earliest, the original drug research and development by the new base company, December 27, 2005 by the United States Food and Drug Administration (FDA) approved the listing, 2013 approved to enter the Chinese market, January 23, that year, to nadoamine to "Rui Fumei" commodity name officially listed in China, the capsule, the specifications of 5 mg, 10 mg, 15 mg, 25 mg, which is 25 mg pricing.
public data show that the new base of Swiss 2019 global sales of $10,918 million, ranked third in the global best-selling drug list, the list of heavyweight drugs, the first-ranked AbbVie's Adamum single resistance, second-ranked Mercato's Paboli bead resistance, and the number one in the place of the After Johnson and Johnson's Ibtini, Squipbo/Ono Pharmaceuticals' NavuliU serotonin, Roche's Beval-Zhuszsar, Pfizer's and Squippel's Apixab, Bayer and Regeneron's Abersip, Pfizer and Ampin's Inasip, Roche's Litoxi.
, the world's best-selling TOP10 drug sales totaled $94 billion - of which the top three products were: Adamu monoantinosis of $19.169 billion; Paboli-Zhu-Singtag 11.048 billion; and Naramine $10.823 billion.
notable, last year, it was also the first time that the amine entered the $10 billion club.
sales of nadomine rose 11.8 percent from a year earlier, according to the latest earnings data from New base.
comes after Newbase's 2018 earnings showed sales of the company rose to $9,685 million in 2018, close to the $10 billion mark.
data show that in recent years, the global sales of nadomine has maintained double-digit growth, is one of the world's best-selling cancer drugs, the market has great potential.
According to the statistics of the world's best-selling drugs, in 2005, the sales performance of the new base of naratallin was only 0.03 billion U.S. dollars, in 2007 it exceeded $500 million, in 2008 it exceeded $1 billion, in 2010 it exceeded $2 billion, in 2012 it exceeded $3 billion, and in 2013 it broke through. US$4 billion, usd$5 billion in 2014, nearly US$6 billion in 2015, nearly US$7 billion in 2016, US$8 billion in 2017, US$9.685 billion in 2018 and US$10.823 billion in global sales in 2019.
it's worth noting that with the increasing number of new indications and the increase in sales year by year, the indomine has now become the number one heavy drug in the field of small molecule anti-tumor drugs.
2, the domestic market 1-3 pattern appears: the new base, shuangyu, sunny, Qilu so far, to nado amine listed in the domestic market in addition to the original research and pharmaceutical enterprises new base, there are three local pharmaceutical companies, respectively, Shuangyi Pharmaceuticals, Zhengda Qing, Qilu Pharmaceuticals.
Beijing Shuangyu Pharmaceuticals was the first to obtain a drug registration approval and new drug certificate for nadoamine capsules on November 21, 2017.
The nadoamine capsule, which is
, was approved for sale in January 2019 (approved for 25mg) and approved for indications in line with the original drug.
on October 30 last year, the day and the sun came to the amine through a consistency evaluation.
November 21, 2019, China Biopharmaceuticalannounced that its subsidiary Zhengda Qing's anti-tumor drug tonadoamine capsule (commodity name "Anxian") has been issued by the State Drug Administration for the approval of the drug supplement application, adding 5mg and 10mg of two specifications.
China Biopharma said the approval of the new specifications will enrich the Group's product line to meet different market needs.
May 9, 2019, Qilu Pharmaceuticals announced that the nadoamine capsule "Zipuyi" (commodity name) has been approved for the market, and is the first of the same variety to pass a consistent evaluation of the product.
from the above three enterprises approved the situation, Beijing Shuangyi Pharmaceuticals listed as early as November 2017, and in June 2020 formally passed the consistency evaluation;
up to now, the domestic approved three to nadoamine capsule enterprises all through the consistency evaluation.
whether it is the selection of varieties of national drug collection, or the relevant policy orientation of the domestic generic drug consistency evaluation, for chemicals, all make the consistency evaluation enterprises full of 3 become an important node and signal.
different from the outstanding performance of the international market, The net data show that the domestic market of nadoamine at the beginning of the performance is not ideal, 2013 to 2017 in the five years, the market growth rate of nadoamine is not very fast, mainly subject to the high price of patented drugs, but also has not yet entered health insurance.
July 2017, through the state negotiations, the price of nadoamine was included in the 2017 version of the national medical insurance drug catalog Class B range, the price from 2799 yuan (25 mg/grain) to 1101.99 yuan (25 mg/grain), followed by a significant market volume, especially into 2019, the sales of indoamine capsules increased to 710 million yuan. In 2019, Xinji has a market share of 68.4%, Zhengda Qing has a 23.3% share and Beijing Shuangyu and Qilu Pharmaceuticals will have a market share of 8.34 percent, according to
.S.A.
in addition to the above four pharmaceutical companies, is declaring to that doamine is yangzijiang pharmaceutical industry, Howson Pharmaceuticals and more than 10 well-known pharmaceutical companies, with more domestic pharmaceutical companies to declare the products listed, to nadoamine market competition situation may be further strained.
.